donepezil has been researched along with Breast Neoplasms in 2 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some breast cancer survivors report cognitive difficulties greater than 1 year after chemotherapy." | 6.82 | A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. ( Balcueva, EP; Case, LD; Griffin, L; Groteluschen, DL; Lawrence, JA; Lesser, GJ; Naughton, MJ; Rapp, SR; Samuel, TA; Shaw, EG, 2016) |
| "Some breast cancer survivors report cognitive difficulties greater than 1 year after chemotherapy." | 2.82 | A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. ( Balcueva, EP; Case, LD; Griffin, L; Groteluschen, DL; Lawrence, JA; Lesser, GJ; Naughton, MJ; Rapp, SR; Samuel, TA; Shaw, EG, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osataphan, N | 1 |
| Phrommintikul, A | 1 |
| Leemasawat, K | 1 |
| Somwangprasert, A | 1 |
| Apaijai, N | 1 |
| Suksai, S | 1 |
| Sirikul, W | 1 |
| Gunaparn, S | 1 |
| Chattipakorn, SC | 1 |
| Chattipakorn, N | 1 |
| Lawrence, JA | 1 |
| Griffin, L | 1 |
| Balcueva, EP | 1 |
| Groteluschen, DL | 1 |
| Samuel, TA | 1 |
| Lesser, GJ | 1 |
| Naughton, MJ | 1 |
| Case, LD | 1 |
| Shaw, EG | 1 |
| Rapp, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo-controlled Trial of Ashwagandha (Withania Somnifera) for Cognitive Dysfunction Associated With Cancer Chemotherapy.[NCT04092647] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for donepezil and Breast Neoplasms
| Article | Year |
|---|---|
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Topics: Breast Neoplasms; Cardiotoxicity; Donepezil; Doxorubicin; Female; Humans; Leukocytes, Mononuclear; M | 2023 |
A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy.
Topics: Adult; Affect; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Cognition; | 2016 |